Celcuity Inc. reported its financial results for the second quarter ended June 30, 2024, revealing increased operating expenses and net loss compared to the prior year. Total operating expenses for Q2 2024 were $24.3 million.
Research and development (R&D) expenses reached $22.5 million for the second quarter of 2024. General and administrative (G&A) expenses were $1.8 million for the same period.
The company reported a net loss of $23.7 million, or $0.62 loss per share, for the second quarter of 2024. Non-GAAP adjusted net loss was $22.2 million, or $0.58 loss per share.
Net cash used in operating activities for the second quarter of 2024 was $18.1 million. These financial figures reflect the ongoing investment in advancing Celcuity's clinical development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.